John Smyth, MD, on The Current State of Cancer Research and Treatment: The European Perspective

2015 ASCO Annual Meeting

John Smyth, MD, of the University of Edinburgh, discusses oncology from an international point of view.

Andrew James Martin, PhD, and Anthony J. Olszanski, RPh, MD, on Oral Nicotinamide to Reduce Nonmelanoma Skin Cancers

Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-risk patients (Abstract 9000).

Hematologic Malignancies

Ruben A. Mesa, MD, and James O. Armitage, MD

Ruben A. Mesa, MD, and James O. Armitage, MD, Results of the PERSIST-1 Study on Myelofibrosis

James O. Armitage, MD, of The University of Nebraska Medical Center, and Ruben A. Mesa, MD, of the Mayo Clinic, discuss pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).

Skin Cancer

Claus Garbe, MD, and Anthony J. Olszanski, RPh, MD

Claus Garbe, MD, and Anthony J. Olszanski, RPh, MD, on The DECOG Trial on Sentinel Lymph Node–Positive Melanoma

Claus Garbe, MD, of the University of Tuebingen, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss the survival of sentinel lymph node-positive melanoma patients with and without complete lymph node dissection (Abstract LBA9002).

Breast Cancer

Andrew D. Seidman, MD, and Clifford A. Hudis, MD

Andrew D. Seidman, MD, and Clifford A. Hudis, MD, on Breast Cancer Decision Analysis

Clifford A. Hudis, MD, and Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, discuss the use of the decision support system Watson for Oncology and results of the iCanCare study on second opinions (Abstracts 566 and 6508).

Supportive Care

Symptom Management

Palliative Care

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

Daniel A. Vorobiof, MD, of the Sandton Oncology Centre, and Bernardo Leon Rapoport, MD, of The Medical Oncology Centre of Rosebank, discuss the first study to evaluate the efficacy and safety of a single dose of intravenous fosaprepitant. The use of this NK1 inhibitor and another (rolapitant) in a second study discussed may change the management of chemotherapy-induced nausea and vomiting and improve quality of life for patients (Abstracts 9629 and 9615).

Nov

Today In Oncology

John Smyth, MD, on The Current State of Cancer Research and Treatment: The European Perspective

Related Videos

Andrew James Martin, PhD, and Anthony J. Olszanski, RPh, MD, on Oral Nicotinamide to Reduce Nonmelanoma Skin Cancers

Ruben A. Mesa, MD, and James O. Armitage, MD, Results of the PERSIST-1 Study on Myelofibrosis

Claus Garbe, MD, and Anthony J. Olszanski, RPh, MD, on The DECOG Trial on Sentinel Lymph Node–Positive Melanoma

Andrew D. Seidman, MD, and Clifford A. Hudis, MD, on Breast Cancer Decision Analysis

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

Triplet Therapy With Abiraterone Improves OS Long-Term in Metastatic Castration-Sensitive Prostate Cancer

FDA Approves Durvalumab With Enfortumab Vedotin-ejfv for Muscle-Invasive Bladder Cancer

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

American Cancer Society Updates Prostate Cancer Screening Guideline

Phase III VOLGA Trial Explores Outcomes in Muscle Invasive Bladder Cancer